AF
SMMT icon

Advisornet Financial’s Summit Therapeutics SMMT Stock Holding History

Advisornet Financial’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.14K Hold
353
– – ﹤0.01% 1756
2026
Q1 		$6.69K Buy
353
+125
+55% +$2.02K ﹤0.01% 1659
2025
Q4 		$3.99K Buy
+228
New +$4.29K ﹤0.01% 1780
2025
Q3 		– Sell
-22
Closed -$468 – 2327
2025
Q2 		$468 Hold
22
– – ﹤0.01% 2068
2025
Q1 		$424 Buy
+22
New +$441 ﹤0.01% 1990

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Advisornet Financial's SMMT Position: Q2 2026 in Review

Advisornet Financial held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 353 shares worth $5.14K. The position accounts for ﹤0.01% of the portfolio, ranked #1756.

Advisornet Financial first reported a position in SMMT in Q1 2025 and has held it in 5 quarters since. The position peaked at $6.69K in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Advisornet Financial held 353 shares of Summit Therapeutics worth $5.14K as of Q2 2026.
  • Advisornet Financial left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Advisornet Financial's portfolio in Q2 2026, its #1756 holding.
  • Advisornet Financial first reported a position in Summit Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Advisornet Financial's Summit Therapeutics position peaked at $6.69K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Advisornet Financial's 13F filing for Q2 2026, filed 23 Jul 2026.